Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds
Translational Radiotheranostics

Junior Research Group Translational Radiotheranostics

Dr. Martina Benesova

The main goal of E270 is to improve Targeted Alpha Therapies (TAT). To achieve this goal, three main areas closely related to alpha-particle emitting radionuclides - radiobiology, drug design and immunology – are investigated.

With rapid population growth and aging, cancer is expected to rank as the leading cause of death in every country of the world in the 21st century. The development of improved diagnostic and therapeutic strategies for the management of cancer is, therefore, of utmost importance. Targeted Radionuclide Therapy (TRNT) or “endoradiotherapy” is an attractive treatment option, where radionuclides are directed to particular cancer-associated targets (receptors, antigens, enzymes or other molecular structures) by specific binders. While external beam radiation (conventional radiotherapy) is highly effective in treating local tumors, TRNT has emerged as an effective therapeutic strategy for disseminated (metastasized) disease. Currently, Targeted Alpha Therapy (TAT) represents the most rapidly developing field in nuclear medicine. Alpha particles have high Linear Energy Transfer (LET; 50–230 keV/µm) significantly enhancing relative biological effectiveness of TAT as compared to other commonly used radionuclide therapies. In addition, short penetration depth of 50–100 µm (6 cell diameters) limits damage to the surrounding healthy tissue. Moreover, based on the critical role of the immune system in cancer development and dissemination, TAT may potentially be combined with various strategies triggering immune response in order to achieve enhanced anti-tumor effect and prolonged remission in cancer patients.

The Junior research group Translational Radiotheranostics pursues highly innovative projects at the frontiers of interdisciplinary cancer research. Our group focuses in particular on alpha particle-emitting radionuclides (e.g., Th-227, Ac-225 and Ra-223), their coordination properties, their physicochemical effects and the respective radiation-induced immune responses and the underlying molecular pathways in the tumor tissue and its microenvironment. In other words, we investigate the mechanisms of effectiveness and resistance towards TAT, with the aim to identify novel cancer targets and therapeutic radiopharmaceuticals. Moreover, we also focus on other prospective therapies which might be beneficially combined with TAT in the future. Successful pre-clinical outcome of above described projects is seen as a powerful basis for the transition towards a contemporary personalized and precision medicine.


Dr. Martina Benesova
Translational Radiotheranostics (E270)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 223
69120 Heidelberg
Tel: +49 6221 42 5355

Selected Publications

  • Tas H, Bakos G, Bauder-Wüst U, Schäfer M, Remde Y, Roscher, Benešová-Schäfer M. Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake? Pharmaceuticals 2024; 17(4): 513.
  • Bauder-Wüst U, Schäfer M, Winter R, Remde Y, Roscher M, Breyl H, Poethko T, Tömböly C, Benešová-Schäfer M. Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals. Appl Radiat Isot 2023; 197: 110819.
  • Roscher M, Bakos G, Benešová M. Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management? Pharmaceuticals 2020; 13(4): E76.
  • Benešová M, Bauder-Wüst U, Schäfer M, Klika KD, Mier W, Haberkorn U, Kopka K, Eder M. New linker modifications influence the PSMA targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J Med Chem 2016; 59(5): 1761.
to top
powered by webEdition CMS